Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Proxalutamide in Hospitalized COVID-19 Patients
NCT05009732Phase 3Terminated
- Sponsor
- Kintor Pharmaceutical Limited
- Start
- Sep 2021
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of proxalutamide in coronavirus disease 2019 (COVID-19), sponsored by Kintor Pharmaceutical Limited. Started Sep 2021; status: terminated.
02
Drugs
proxalutamide
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05009732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05009732.